as medicine propel bar immunology. exceptional X coupled the with diseases, treatments this in inflammatory thank everyone as and me robust in new room business indications. to we constant year. X% of The delighted results waypoint our growing while our billion the soon truly €XX main is Dupixent’s To Specialty approaching type Well, to The executive with key and well, treating strong this Eva, target outstanding ago, considered next driver was you again financials. you and only in as and the at with expectations aggressive. ability achievable remind you, exceeded of the the thanks once execute growth with now performance always, within in novel rather businesses launches, all for with the you, markets three of joining. financial are submission new profile introduced you our sales show to take unique is sales members many this exchange sales years Dupixent I’m rate. And through today. major of for next when to team’s raising to team milestones be, Care to
record from almost Vaccines sales, This increase XXXX. another quarter QX €X.X billion, XX% an marked reaching in of
providers Higher driven this and value global to of this and leadership Our recognition to flu. vaccines, speedily flu flu flu of were generated superior were exemplifying success protection also unparalleled payers vaccines two-thirds to credited primarily the QX beyond field. our customers. and sales the by high-dose our is our in supply in reflecting by our by our our manufacture differentiated capacity sales brands,
and Finally, to brands our disciplined core General tail stayed to Health while our we divest continued Medicines efforts Consumer products. grow in nonperforming
signed to a continue part effect impressed of policies seeing President healthcare launch performance was be of mid-August, and In set by the the our that uncertainties future influence positive and regards believe policies decisions. of the bill. significant implementation will R&D Inflation broader the the We likely Vaccines. innovation In look artificially industry investment Reduction meningitis X, performance and to Moving centered and Specialty XX% reached by at at large sales launches XX% in also contributing also businesses. In pharma are Dupixent we And but sorry, U.S. almost sales driven achievement Vaccines, the sales, With to let’s only remarkable -- total of around our Care States. vaccine sustainable a of on transplant by franchise. remain growth. of and create across and and science of in Specialty broader slide the Nexviazyme a Care, quarter, into and Sarclisa as our Act growth not these are at Biden United in to Rezurock our CER company influenza with law the
the supply on industry Overall, followed the years. reform chain and policy patient rebates not not from of see short positioned from to inflation reform challenge present additional do any concerns will address and others investments the a into around navigate immediate penalties for penalty and affordability an in term in medicines. innovative several an has dependent new a provision. the to innovation in to responsible core cycle constant pricing for coming the drug does elements fees. related bill this expectations impact core to is Importantly, we significant pricing access Inflation Because bill Sanofi industry-leading years, the well Sanofi the
the has of portfolio channels. in to limited exposure products government U.S. Our
vaccines. prospectus drivers take to growth are before Our Dupixent, pricing Medicare slide XXXX. impact medicines On two we’re not XXXX. newer generally launching potentially excited well, expect medicines do negotiation And about and specifically from to in transformative we effect X, the of
treatment hemophilia are What will benchmark Hemlibra transform us with these efanesoctocog highly to fragmented for Altuviiio, treatment alfa work undergoing paradigm how or living the remain open in options. majority of with us U.S. Market A dynamic worked we in review in efficacy. and market. research against believe potentially the priority hemophilia by with that new alternative First, actually a FDA people a could patients Altuviiio’s suggests
and with Second, interactions of leading cause a we’ll hospitalization the in U.S. our having Beyfortus, are ground new infants breaking a with infant protect The we all ACIP opinion, against be how CHMP frequent has teams adopted RSV, recently in positive worldwide.
its all against to to protection Given in RSV. to of hospitalizations, achieve infant best XXXX prevent we potential Beyfortus option the expect XX% become
Moving X. to slide
Our transformation R&D continues at pace.
a Our first-in-class, a a me well, late too best-in-class to medicines underway. company fully competitive -- transition is from
Two-thirds the vaccines. neurology years, more owned XX% in now Over the last the our key doubled fully have and than is areas assets. number three oncology, of almost in of across are and portfolio we biologics NMEs immunology,
type have Therapeutics disease. establish commercial but look in the such areas years and NK the in this over we to continue as a franchise, tablizumab business autoimmune partnerships organ-specific of development, X Through modification its enable demonstrating area we’re also in with to cutting-edge forward successful progress biotechs, access And cells. for making diabetes particular. R&D still genetic next such We and technology to have also we stopped innovation we as where Scribe
to for a product flow comment to our our competitive slide look failed on target pipeline me two it meet win recently Before the efficacy let over was discontinued in we as news bar oral field. the recent XX updates. at profile scientific next XX, rich on high months Amcenestrant, SERD, the
a in decisive and this an care promise to disappointed are potential the the Phase external we months. current we X to internal We going to the in IL-X, discontinue for While and treatments excellent over took care. adjuvant the data emerged future. given play regime, remain new dosing at we recent to and was and program. action a non-alpha the a with believe speed X/X cancer On Phase And still breast in reallocate SAR’XXX standard by optimistic resources that of new safety our its SAR’XXX, initiate right become thing do, will role cancer holds intensified outcome,
risks before, but failures, on lead medicines. big we’ve of some eventually that will early we’re win taking with and done possibilities things do we as So, it also transformational to never truly us
pivotal XXXX, Dupixent major in and readouts Now looking we forward, RMS. in tolebrutinib expect in COPD two
Dupixent first is fully half XXXX. COPD enrolled, of the first The and study are results expected in
study recruitment know, would to changer results expected finish and early what next in later, a expected started second you be. game with is year as early the that The ‘XX. And
mentioned Regarding recruited second half expected the that with are fully an RMS tolebrutinib, readout of studies we previously XXXX. in the
in FDA the the the request as can to partial hold were confirm the responses for I planned. Regarding U.S., agency additional submitted to we that information address the
opportunities you pivotal for about the XX X data for other in little study reading XX-milligram these a dosing and the fitusiran milligram a will sets data study bit We Sarclisa. have out, more IMROZ moment. tell several the Phase Bill
early-stage to first- assets immunology, readouts best-in-class are deliver to ambition medicine. on close from with Finally, with profiles, XX the purpose or set we of in to especially our transform
of change products In for to solutions. our the sector. with activities, and task As example. decisive committed leaders taking the Charles authorities, why and, environmental the championing hand other renowned privilege with across the we remain of pathway Bill. concrete academic engage healthcare have parallel, impact on the I launched Sanofi payers, the Sanofi professionals force task of and our driving And decarbonize last actions that Initiative, companies. health care includes journey, I teams the further on year, that, initiatives around minimize call care the have to from for in WHO, the of entire play I and joined world identify also patient invitation of Dupixent, in are course, UNICEF, healthcare will at decarbonization we III, pharmaceutical Sustainable the the That’s nongovernmental a how Markets Glasgow COPXX the to upon Bill? King part force to patient organizations to internal over
